(Q30438803)

English

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

1

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Angeles Alvarez Secord

2

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kathleen M Darcy

3

object named as

Kathleen M Darcy

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Gynecologic Oncology Group

6

object named as

Gynecologic Oncology Group

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Deborah K Armstrong

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Shalini Kulasingam

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

25

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4144-4150

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Short versus long duration infusions of paclitaxel for any adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Future of end-of-life care: the managed care organization perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

20 June 2018

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

26 November 2018

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

26 November 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

26 November 2018

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654369

26 November 2018

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

United States life tables, 2003

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18757328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.13.1961

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30438803&oldid=1739979985"